Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401952 | 1.00 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1401951 | 1.00 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL12003121 | 1.00 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL8960068 | 1.00 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL3714471 | 1.00 | LMNA (0.41) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL242481 | 0.93 | LMNA (0.40) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL13177712 | 0.91 | HTR2C (0.38) | HTR2CHTR2BTMIGD3ADORA3ADORA1 | |
| SCHEMBL4352873 | 0.91 | LMNA (0.39) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL13211904 | 0.89 | LMNA (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL10158794 | 0.86 | ADORA3 (0.53) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322525-B1 | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| WO-2009050198-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| EP-2018382-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1903044-A1 | Adenosine Derivatives as A2A Receptor Agonists | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121917-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | LMNA 1663/4885TP53 4506/4885ALDH1A1 918/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885TP53 969/4885ALDH1A1 166/4885 |
| US-20090181934-A1 | Organic Compounds | LTB4R2, LTA4H, LTB4R | LMNA 2511/4885TP53 3430/4885ALDH1A1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.